시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 알레르기 질환용 표적 약물 시장 : 분석 및 예측(-2030년)
Global Targeted Drugs for Allergic Diseases Market Insights, Forecast to 2030
상품코드 : 1432271
리서치사 : QYResearch
발행일 : 2024년 02월
페이지 정보 : 영문
 라이선스 & 가격 (부가세 별도)
US $ 4,900 ￦ 7,092,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트 등을 Copy & Paste 할 수 있습니다. 인쇄 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,350 ￦ 10,638,000
PDF (Multi User License) help
PDF, Excel 보고서를 동일 기업내 10명까지 이용하실 수 있는 라이선스입니다. 텍스트 등을 Copy & Paste 할 수 있습니다. 인쇄 가능하며, 인쇄물의 이용 범위는 PDF, Excel, Word 이용 범위와 동일합니다.
US $ 9,800 ￦ 14,184,000
PDF (Enterprise User License) help
PDF, Excel, Word 보고서를 동일 기업내 모든 구성원이 이용하실 수 있는 라이선스입니다. 텍스트 등을 Copy & Paste 할 수 있습니다. 인쇄 가능하며, 인쇄물의 이용 범위는 PDF, Excel, Word 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 알레르기 질환용 표적 약물 시장 규모는 2024년 371억 4,912만 달러에서 2030년까지 910억 6,996만 달러에 이르고, 예측 기간에 연평균 복합 성장률(CAGR) 16.12%의 성장이 전망됩니다.

미국/캐나다 시장은 2024년 248억 1,798만 달러에서 2030년까지 474억 4,929만 달러에 이를 것으로 추정되며, 2025년-2030년 예측 기간 동안 연평균 복합 성장률(CAGR)은 11.41%를 나타낼 전망입니다.

중국 시장은 2024년 23억 336만 달러에서 2030년까지 165억 2,416만 달러에 이를 것으로 추정되며, 예측 기간 동안 연평균 복합 성장률(CAGR)은 38.88%를 나타낼 전망입니다.

유럽 시장은 2024년 65억 9,313만 달러에서 2030년까지 157억 486만 달러에 이를 것으로 추정되며, 예측 기간 동안 연평균 복합 성장률(CAGR)은 15.56%를 나타낼 전망입니다.

세계의 알레르기 질환용 표적 약물 주요 기업은 Sanofi, AbbVie, Novartis, Incyte, Roche, AstraZeneca, GSK, Eli Lilly and Company, Amgen, Pfizer, Leo Pharma, Teva, Otsuka Pharmaceutical, Mabpharm 등입니다. 2023년 세계 주요 5개사의 매출 점유율은 약 75.25%였습니다.

세계의 알레르기 질환용 표적 약물 시장에 대해 조사 분석했으며, 각 지역 시장 규모와 예측, 시장 역학, 경쟁 구도 등의 정보를 제공합니다.

목차

제1장 보고서 개요

제2장 세계의 성장 동향

제3장 경쟁 구도 : 주요 기업별

제4장 알레르기 질환용 표적 약물 분석 데이터 : 유형별

제5장 알레르기 질환용 표적 약물 분석 데이터 : 용도별

제6장 북미

제7장 유럽

제8장 중국

제9장 아시아(중국 제외)

제10장 라틴아메리카

제11장 중동 및 아프리카

제12장 주요 기업 개요

제13장 애널리스트의 견해/결론

제14장 부록

LSH
영문 목차

영문목차

The global Targeted Drugs for Allergic Diseases market is projected to grow from US$ 37,149.12 million in 2024 to US$ 91,069.96 million by 2030, at a Compound Annual Growth Rate (CAGR) of 16.12% during the forecast period.

The US & Canada market for Targeted Drugs for Allergic Diseases is estimated to increase from $ 24,817.98 million in 2024 to reach $ 47,449.29 million by 2030, at a CAGR of 11.41% during the forecast period of 2025 through 2030.

The China market for Targeted Drugs for Allergic Diseases is estimated to increase from $ 2,303.36 million in 2024 to reach $ 16,524.16 million by 2030, at a CAGR of 38.88% during the forecast period of 2025 through 2030.

The Europe market for Targeted Drugs for Allergic Diseases is estimated to increase from $ 6,593.13 million in 2024 to reach $ 15,704.86 million by 2030, at a CAGR of 15.56% during the forecast period of 2025 through 2030.

The global key companies of Targeted Drugs for Allergic Diseases include Sanofi, AbbVie, Novartis, Incyte, Roche, AstraZeneca, GSK, Eli Lilly and Company, Amgen, Pfizer, Leo Pharma, Teva, Otsuka Pharmaceutical, Mabpharm etc. In 2023, the global top five players had a share approximately 75.25 % in terms of revenue.

Report Includes

This report presents an overview of global market for Targeted Drugs for Allergic Diseases market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Targeted Drugs for Allergic Diseases, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Targeted Drugs for Allergic Diseases, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Targeted Drugs for Allergic Diseases revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Targeted Drugs for Allergic Diseases market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Targeted Drugs for Allergic Diseases revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Sanofi, Novartis, GSK, Amgen, AstraZeneca, Pfizer, TEVA, Otsuka Pharmaceutical, and Roche, etc.

Market Segmentation

By Company

Segment by Type

Segment by Application

By Region

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Targeted Drugs for Allergic Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Targeted Drugs for Allergic Diseases companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Targeted Drugs for Allergic Diseases revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions

Table of Contents

1 Report Overview

2 Global Growth Trends

3 Competition Landscape by Key Players

4 Targeted Drugs for Allergic Diseases Breakdown Data by Type

5 Targeted Drugs for Allergic Diseases Breakdown Data by Application

6 North America

7 Europe

8 China

9 Asia (excluding China)

10 Latin America

11 Middle East & Africa

12 Key Players Profiles

13 Analyst's Viewpoints/Conclusions

14 Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기